Vaš brskalnik ne omogoča JavaScript!
JavaScript je nujen za pravilno delovanje teh spletnih strani. Omogočite JavaScript ali pa uporabite sodobnejši brskalnik.
Repozitorij Univerze v Ljubljani
Nacionalni portal odprte znanosti
Odprta znanost
DiKUL
slv
|
eng
Iskanje
Napredno
Novo v RUL
Kaj je RUL
V številkah
Pomoč
Prijava
Podrobno
Heart failure in Europe : Guideline-directed medical therapy use and decision making in chronic and acute, pre-existing and de novo, heart failure with reduced, mildly reduced, and preserved ejection fraction - the ESC EORP Heart Failure III Registry
ID
Lund, Lars H.
(
Avtor
),
ID
Lainščak, Mitja
(
Avtor
), et al.
PDF - Predstavitvena datoteka,
prenos
(1,04 MB)
MD5: 01BDAC8D8A6F16DE14DFD86400F1F843
URL - Izvorni URL, za dostop obiščite
https://onlinelibrary.wiley.com/doi/10.1002/ejhf.3445
Galerija slik
Izvleček
Aims: We analysed baseline characteristics and guideline-directed medical therapy (GDMT) use and decisions in the European Society of Cardiology (ESC) Heart Failure (HF) III Registry. Methods and results: Between 1 November 2018 and 31 December 2020, 10 162 patients with acute HF (AHF, 39%, age 70 [62-79], 36% women) or outpatient visit for HF (61%, age 66 [58-75], 33% women), with HF with reduced (HFrEF, 57%), mildly reduced (HFmrEF, 17%) or preserved (HFpEF, 26%) ejection fraction were enrolled from 220 centres in 41 European or ESC-affiliated countries. With AHF, 97% were hospitalized, 2.2% received intravenous treatment in the emergency department, and 0.9% received intravenous treatment in an outpatient clinic. AHF was seen by most by a general cardiologist (51%) and outpatient HF most by a HF specialist (48%). A majority had been hospitalized for HF before, but 26% of AHF and 6.1% of outpatient HF had de novo HF. Baseline use, initiation and discontinuation of GDMT varied according to AHF versus outpatient HF, de novo versus pre-existing HF, and by ejection fraction. After the AHF event or outpatient HF visit, use of any renin-angiotensin system inhibitor, angiotensin receptor-neprilysin inhibitor, beta-blocker, mineralocorticoid receptor antagonist and loop diuretics was 89%, 29%, 92%, 78%, and 85% in HFrEF; 89%, 9.7%, 90%, 64%, and 81% in HFmrEF; and 77%, 3.1%, 80%, 48%, and 80% in HFpEF. Conclusion: Use and initiation of GDMT was high in cardiology centres in Europe, compared to previous reports from cohorts and registries including more primary care and general medicine and regions more local or outside of Europe and ESC-affiliated countries.
Jezik:
Angleški jezik
Ključne besede:
ejection fraction
,
guideline-directed medical therapy
,
heart failure
,
implementation
,
quality of care
,
registry
Vrsta gradiva:
Članek v reviji
Tipologija:
1.01 - Izvirni znanstveni članek
Organizacija:
MF - Medicinska fakulteta
Status publikacije:
Objavljeno
Različica publikacije:
Objavljena publikacija
Leto izida:
2024
Št. strani:
Str. 2487-2501
Številčenje:
Vol. 26, iss. 12
PID:
20.500.12556/RUL-182442
UDK:
616.1
ISSN pri članku:
1388-9842
DOI:
10.1002/ejhf.3445
COBISS.SI-ID:
225964035
Datum objave v RUL:
12.05.2026
Število ogledov:
124
Število prenosov:
69
Metapodatki:
Citiraj gradivo
Navadno besedilo
BibTeX
EndNote XML
EndNote/Refer
RIS
ABNT
ACM Ref
AMA
APA
Chicago 17th Author-Date
Harvard
IEEE
ISO 690
MLA
Vancouver
:
Kopiraj citat
Objavi na:
Gradivo je del revije
Naslov:
European journal of heart failure
Skrajšan naslov:
Eur. j. heart fail.
Založnik:
Elsevier
ISSN:
1388-9842
COBISS.SI-ID:
1217301
Licence
Licenca:
CC BY-NC-ND 4.0, Creative Commons Priznanje avtorstva-Nekomercialno-Brez predelav 4.0 Mednarodna
Povezava:
http://creativecommons.org/licenses/by-nc-nd/4.0/deed.sl
Opis:
Najbolj omejujoča licenca Creative Commons. Uporabniki lahko prenesejo in delijo delo v nekomercialne namene in ga ne smejo uporabiti za nobene druge namene.
Sekundarni jezik
Jezik:
Slovenski jezik
Ključne besede:
iztisni delež
,
s smernicami usmerjena medicinska terapija
,
srčno popuščanje
,
implementacija
,
kakovost oskrbe
,
register
Projekti
Financer:
Abbot Vascular Int.
Financer:
Amgen Cardiovascular
Financer:
AstraZeneca AB
Financer:
Bayer AG
Financer:
Boehringer Ingelheim
Financer:
Bristol Myers Squibb
Financer:
Daichii Sankyo Europe GmbH
Financer:
Edwards Lifesciences
Financer:
Novartis Pharma AG
Financer:
Servier
Financer:
Vifor
Podobna dela
Podobna dela v RUL:
Podobna dela v drugih slovenskih zbirkah:
Nazaj